Stevanato Group (NYSE:STVN) Announces Earnings Results

Stevanato Group (NYSE:STVN) announced its quarterly earnings results on Tuesday. The company reported €0.12 ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of €0.13 ($0.14) by (€0.01) (($0.01)), Briefing.com reports. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. The business had revenue of €277.90 million for the quarter, compared to analysts’ expectations of €274.36 million. During the same period last year, the firm earned $0.16 earnings per share. The firm’s quarterly revenue was up 2.4% on a year-over-year basis. Stevanato Group updated its FY 2024 guidance to 0.517-0.539 EPS and its FY24 guidance to €0.47-0.49 EPS.

Stevanato Group Stock Performance

Shares of NYSE STVN traded up €0.05 ($0.05) during trading hours on Friday, reaching €22.77 ($25.02). The stock had a trading volume of 189,311 shares, compared to its average volume of 509,255. The firm has a 50-day moving average of €19.68 and a 200-day moving average of €20.33. The firm has a market cap of $6.73 billion, a price-to-earnings ratio of 48.34, a PEG ratio of 10.18 and a beta of 0.58. The company has a current ratio of 1.81, a quick ratio of 1.13 and a debt-to-equity ratio of 0.22. Stevanato Group has a fifty-two week low of €16.56 ($18.20) and a fifty-two week high of €34.73 ($38.16).

Analyst Ratings Changes

A number of brokerages recently issued reports on STVN. Citigroup lowered their price target on Stevanato Group from $30.00 to $28.00 and set a “buy” rating for the company in a report on Wednesday, August 7th. Morgan Stanley lowered their target price on shares of Stevanato Group from $26.00 to $22.00 and set an “equal weight” rating for the company in a report on Monday, July 15th.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.